Debiopharm
The Audit & CAPA Lead is responsible for overseeing quality assurance audits and managing Corrective and Preventive Action (CAPA) processes within a pharmaceutical environment. This role ensures compliance with regulatory standards and drives continuous improvement initiatives to maintain product quality and safety.
Debiopharm is an independent biopharmaceutical company based in Switzerland dedicated to improving patient outcomes and quality of life, with a focus on oncology and bacterial infections. Its core activities span drug development, drug manufacturing, and investments in digital health. The company covers end-to-end capabilities from research and development to scalable manufacturing and strategic partnerships to bring innovative therapies to patients. Debiopharm combines scientific excellence with a patient-centered approach to translate research into meaningful medicines.
Debiopharm picks up a bargain-basement Wee1 companion | ApexOnco - Clinical Trials news and analysis
Jul 16, 2025
Debiopharm Forges AI-powered Alliance With NetTargets to Pioneer Dual-payload ADCs Against Drug-resistant Cancers
Oct 30, 2025
GARDP, Debiopharm Partner to Develop Novel Gonorrhea Drug
1 month ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Debiopharm.
Debiopharm didn’t post a salary, so this is our estimate from similar listings.
11% below the average for this role
Debiopharm Deploys Genialis Software to Advance AI-Based Biomarker Discovery
1 month ago